Research record

Clinical trial search strategy

A trial-search record that helps families ask better questions without treating a trial listing as proof that a study fits.

What this is

A trial-search record that helps families ask better questions without treating a trial listing as proof that a study fits.

Why it may come up

  • before next treatment line
  • after recurrence
  • mutation-specific search

What not to assume

  • Never say a user qualifies for a trial.

At a glance

Clinical trial search strategy

Used in care guidelinesThis is a commonly recognized treatment category.
Type
Trial search
Mutation result
any
Where
Global
Evidence status
Source gives context
Last checked
2026-05-20

What we know

  • ClinicalTrials.gov and NCI trial sources can identify records that mention melanoma, mutations, drugs, or prior therapy.
  • Registry text can lag or omit details.

What is unclear

  • A trial listing never confirms that a study fits.
  • Recruiting status must be confirmed by the trial team.

Questions to ask

  • Should we search trials before starting the next treatment?
  • Which terms should we search?
  • Who can contact the trial team?

Related trial leads

NCT03973151

Study of HL-085 in NRAS Mutant Advanced Melanoma

Primary early clinical trial record for HL-085/tunlametinib in NRAS-mutant melanoma that has spread or cannot be removed easily.

This record is not the exact tunlametinib plus nivolumab combination remembered by the user.

NCT06008106

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.

A trial listing match does not mean the trial fits. The trial team must confirm.

NCT04835805

Belvarafenib alone or with cobimetinib or cobimetinib plus nivolumab in NRAS-mutant advanced melanoma

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

NCT03979651

Trametinib plus hydroxychloroquine in NRAS melanoma

NRAS melanoma research lead involving MEK inhibition and autophagy inhibition.

Trial record does not make this a routine treatment option.

Related cohort stories

Open related treatment page